TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05612828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional versus simulation manikin training
Description: Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional versus simulation manikin training
Description: Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
Study: NCT05895019

Intervention type: DRUG
Intervention: Propofol
Description: Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.

Intervention type: DRUG
Intervention: Propofol
Description: Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.
Study: NCT05289895

Intervention type: OTHER
Intervention: No intervention
Description: This study was an observational trial without any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This study was an observational trial without any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This study was an observational trial without any intervention
Study: NCT05334212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Theater
Description: The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
Study: NCT04972617

Intervention type: DIAGNOSTIC_TEST
Intervention: albumin function analysis (ABIC)
Description: After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
Study: NCT05071248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VEMO (Reactive Robotics GmbH)
Description: The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
Study: NCT05028244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: venous ultrasound of lower extremity
Description: Patients are explored for deep vein thrombosis in femoral-popliteal and distal veins of the legs with ultrasound compression and doppler flow evaluation
Study: NCT05425940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: Supplied as tablets; administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
Study: NCT05493800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline IV injection
Study: NCT05136950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary in-the-bag IOL fixation
Description: The experimental group with secondary IOL fixated in the capsular bag

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary ciliary sulcus IOL fixation
Description: The control group with secondary IOL fixated in the ciliary sulcus
Study: NCT05775276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proline mesh in hernioplasty
Description: Hernioplasty using proline mesh then follow up for incidence of infection
Study: NCT05808543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Both EARS training package (BEARS)
Description: The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
Study: NCT04735484

Intervention type: DEVICE
Intervention: Gait analysis
Description: Collecting movement data whilst participants walk

Intervention type: DEVICE
Intervention: Gait analysis
Description: Collecting movement data whilst participants walk
Study: NCT06413849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone coached graphic narrative bibliotherapy
Description: Eight weekly sessions of telephone coached graphic narrative bibliotherapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Reading educational booklet
Study: NCT06355232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine
Description: Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine
Description: Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine
Description: Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant
Study: NCT06423274

Intervention type: DIAGNOSTIC_TEST
Intervention: fundus photography
Description: using artificial intelligence to identify diabetic retinopathy using fundus photography

Intervention type: DIAGNOSTIC_TEST
Intervention: optical coherence tomography
Description: detect diabetic retinopathy and diabetic macular edema by optical coherence tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: fundus fluorescence angiography
Description: detect diabetic retinopathy by fundus fluorescence angiography
Study: NCT04867096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
Study: NCT01209013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlight PDT Balloon
Description: Medlight PDT Balloon will be used once to apply the laser light treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy with biopsy
Description: Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest x-ray
Description: A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood samples for laboratory tests will be taken to assess the overall condition

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue sample collection
Description: Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
Study: NCT06305832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: Specifications of 80 mg; orally, once a day

Intervention type: DRUG
Group type: OTHER
Intervention: Androgen deprivation therapy (ADT)
Description: Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information

Intervention type: RADIATION
Group type: OTHER
Intervention: SRT
Description: SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT
Description: SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
Study: NCT05163899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Release of filum terminale
Description: Surgery will be offered to section the filum terminale
Study: NCT06471335

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extraction of microRNAs extracted from plasma (4 ml recovered as part of treatment)
Description: Comparison of these micro RNAs with the micro RNAs extracted from oral swabs (in Fetal Alcohol Spectrum Disorder group)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of microRNAs extracted from bucal swabs (act added for research).
Description: Comparison of the microRNAs extracted from the oral swabs of the Fetal Alcohol Spectrum Disorder group with the microRNAs extracted from the oral swabs of the without Fetal Alcohol Spectrum Disorder group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extraction of microRNAs extracted from bucal swabs (act added for research).
Description: Comparison of the microRNAs extracted from the oral swabs of the Fetal Alcohol Spectrum Disorder group with the microRNAs extracted from the oral swabs of the without Fetal Alcohol Spectrum Disorder group
Study: NCT06355700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: The liver biopsy is ultrasound-guided and target the hepatic lesions. It is performed with 18G or 19G Menghini needle. A part of bioptic sample will be used for genomic analysis. An other part of sample will be cultured to create the organoid. The organoid's cultures will be integrated with the host gut microbiota (collected by a fecal sample) and peripheral blood mononuclear cells (from venous blood sample) and they will be used for research such as molecular analysis and pharmacological tests.
Study: NCT04976101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinosuidal Galvanic Vestibular Stimulation
Description: stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
Study: NCT04812717

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb device
Description: The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
Study: NCT05360797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical home care
Description: After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospitalization
Description: After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI_1) in each center.
Study: NCT05829226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-200
Description: monoclonal antibody (mAb), targeting galectin-9 protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-200
Description: monoclonal antibody (mAb), targeting galectin-9 protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Bcl-2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Hypomethylating agent
Study: NCT05136924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo
Description: OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study: NCT04722419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probe meal
Description: The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probe meal
Description: The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
Study: NCT05669261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Tissue Harvest
Description: Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adipose Tissue Harvest
Description: Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATCell
Description: Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
Study: NCT06521931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN20
Description: Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
Study: NCT05562219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA108 granules
Description: Take the medication as required for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QA108 granules placebo
Description: Take the medication as required for 24 weeks